A monthly newsletter published by the College of Pharmacy on behalf of the OHA. Provides drug utilization reviews, drug and therapeutic guideline reviews, and cost-effective prescribing recommendations to Medicaid providers and pharmacies throughout Oregon. Each newsletter is offered in PDF format for viewing and printing.
You may elect to receive the newsletter monthly via email subscription through the OSUPHARMDI Listserv.
Volume 14 - 2024 |
||
Issue | Table of Contents | |
No. 10, October 2024 | New and Emerging Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) in Adults | |
No. 9, September 2024 | Respiratory Syncytial Virus – Guidance for the Upcoming Season | |
No. 8, August 2024 | Applying the Science of Pharmacogenomics to Clinical Practice | |
No. 7, July 2024 | Lifestyle Modifications for Obesity: Recommendations and Benefits | |
No. 6, June 2024 | Critical Access Pharmacy Programs | |
No. 5, May 2024 | Safety Risks Associated with Long-Term Use of Proton Pump Inhibitors | |
No. 4, April 2024 | Medication Holidays | |
No. 3, March 2024 | Asthma Relief Inhaler Drug Use Evaluation | |
No. 2, February 2024 | Hepatitis C Care for Primary Care Providers | |
No. 1, January 2024 | Updates for Insomnia: Evidence and Oregon Medicaid Policy |
Volume 13 - 2023 |
||
Issue | Table of Contents | |
No. 9, December 2023 | Opioid Reversal Agents | |
No. 8, November 2023 | Prevention of Respiratory Syncytial Virus (RSV) Infection: New Products and Recommendations | |
No. 7, September 2023 | An Update in Weight Loss Therapies - Including FDA Approved GLP-1 Receptor Agonists | |
No. 6, August 2023 | 2023 Global Initiative for Chronic Obstructive Lung Disease Report: Focus on Revised Recommendations for Inhaler Products | |
No. 5, July 2023 | Update on the Use of SGLT-2 Inhibitors | |
No. 4, May 2023 | Buprenorphine: Place in Therapy for Chronic Pain | |
No. 3, April 2023 | COVID-19 Therapeutics Update: Where Are We Now? (Evidence updated through March 31, 2023) | |
No. 2, February 2023 | Psychotropic Use in Youth Enrolled in the Oregon Health Plan and Youth in Foster Care with an Emphasis on Antipsychotic Prescription - *Correction to Previous Posting | |
No. 1, January 2023 | Early and Periodic Screening, Diagnostic and Treatment (EPSDT) Benefit for Children and Adolescents |
Volume 12 - 2022 |
||
Issue | Table of Contents | |
No. 9, November 2022 | Hormone Replacement Therapy – A Focus on the Benefits and Risks of Estrogen | |
No. 8, October 2022 | Pharmacological Prevention and Treatment of Monkeypox | |
No. 7, September 2022 | COVID-19 Vaccine Bivalent Boosters | |
No. 6, August 2022 | An Update in Lipid Lowering Therapies | |
No. 5, July 2022 | Antimicrobial Stewardship | |
No. 4, May 2022 | Population Trends in the Use of Migraine Preventative Treatments | |
No. 3, April 2022 | Asthma Guidance Update with a Focus on Changes for Managing Patients with Mild Asthma | |
No. 2, March 2022 | Updated 2021 Treatment Guidelines for Sexually Transmitted Infections | |
No. 1, January 2022 | Second-Generation Antipsychotic Use in Children and Adolescents |
Volume 11 - 2021 |
||
Issue | Table of Contents | |
No. 9, December 2021 | A PEP Talk on PrEP-ing for HIV Prevention | |
No. 8, November 2021 | Anti-SARS-CoV-2 Therapeutics can Effectively Treat, Prevent COVID-19 Infection | |
No. 7, September 2021 | Updates in Heart Failure Therapy: New Drugs and Indications | |
No. 6, August 2021 | Therapeutic Uses for Cannabinoids | |
No. 5, July 2021 | Deprescribing Techniques to Minimize Safety Issues Associated with Inappropriate Polypharmacy | |
No. 4, May 2021 | COVID-19 Vaccine Update | |
No. 3, March 2021 | Bipolar Disorder: Resources for Primary Care Providers | |
No. 2, February 2021 | Antidepressant Review | |
No. 1, January 2021 | Coronavirus Disease-2019 Vaccine Update |
Volume 10 - 2020 |
||
Issue | Table of Contents | |
No. 9, December 2020 | 2019-2020 Food and Drug Administration Drug Safety Communications Update | |
No. 8, November 2020 | COVID-19 Viral Testing | |
No. 7, September 2020 | Cardiovascular Outcomes Associated with Newer Therapy Classes for Type 2 Diabetes Mellitus | |
No. 6, August 2020 | New Disease-Modifying Anti-Rheumatic Drugs for Management of Rheumatoid Arthritis | |
No. 5, July 2020 | Shifts in the Treatment of Community Acquired Pneumonia | |
No. 4, May 2020 | Optimizing the Use of NPH Insulin in Patients with Type 2 Diabetes Mellitus | |
No. 3, April 2020 | Coronavirus Management: Evidence for Treatment and Drug Shortage Updates | |
No. 2, March 2020 | Biosimilar Medications: Key Considerations for Providers | |
No. 1, January 2020 | Evidence for Drugs that are Heavily Marketed |
Volume 9 - 2019 |
||
Issue | Table of Contents | |
No. 9, December 2019 | CGRP Antagonists in Migraine Prophylaxis | |
No. 8, November 2019 | Update on Recent Guidance and Safety Alerts for Opioid Use in Non-cancer Pain | |
No. 7, September 2019 | Pearls and Pitfalls of Clinical Practice Guidelines | |
No. 6, August 2019 | Stimulant Use in Excessive Somnolence Disorders | |
No. 5, July 2019 | Oregon Health Authority Mental Health Clinical Advisory Group (MHCAG) Recommendations for the Treatment of Schizophrenia | |
No. 4, May 2019 | Update on Medications Used to Manage Opioid Use Disorder and Opioid Withdrawal | |
No. 3, March 2019 | Non-statin Low-Density Lipoprotein Cholesterol (LDL-C) Lowering Therapy and Cardiovascular Outcomes | |
No. 2, February 2019 | Benzodiazepine Safety and Tapering | |
No. 1, January 2019 | 2017-18 Year in Review: Important Safety Updates |
Volume 8 - 2018 |
||
Issue | Table of Contents | |
No. 7, December 2018 | Basal Insulin Update | |
No. 6, October 2018 | Updates on Testosterone Therapy | |
No. 5, September 2018 | Management Strategies for Patients with Prediabetes | |
No. 4, July 2018 | Update on Treatment Options for Moderate to Severe Atopic Dermatitis | |
No. 3, May 2018 | A Review of Implications of FDA Expedited Approval Pathways, Including the Breakthrough Therapy Designation | |
No. 2, March 2018 | Second Generation Antipsychotic Use in Major Depressive Disorder | |
No. 1, January 2018 | What's New with Biologic Agents for Inflammatory Disease? |
Volume 7 - 2017 |
||
Issue | Table of Contents | |
No. 9, December 2017 | Current Landscape of the Antidepressant Class: First Line Agents, Newer Agents, and Safety Risks | |
No. 8, November 2017 | Marketing Claims of Newer Drugs and the Evidence | |
No. 7, August 2017 | Oral Anticoagulant Update | |
No. 6, July 2017 | Tramadol and Codeine Use In Pediatrics: A Review of Recent FDA Safety Alerts | |
No. 5, June 2017 | New Biologics for Treatment of Moderate to Severe Psoriasis | |
No. 4, May 2017 | Updates in the Management of Chronic Obstructive Pulmonary Disease | |
No. 3, April 2017 | Management of Opioid Use Disorder | |
No. 2, March 2017 | Non-Analgesics for Pain Management | |
No. 1, January 2017 | Treatment of Gout |
Volume 6 - 2016 |
||
Issue | Table of Contents | |
No. 8, December 2016 | Guideline and Policy Updates for Use of Opioids for Non-Cancer Pain and Opioid Use Disorder | |
No. 7, October 2016 | Endocrine Therapy for Breast Cancer | |
No. 6, August 2016 | Vaccine Update 2016 | |
No. 5, July 2016 | Pharmacist Prescribed Contraceptives | |
No. 4, June 2016 | Who Benefits from Calcium and Vitamin D Supplementation | |
No. 3, April 2016 | Autism Spectrum Disorder Still Not Linked to the MMR Vaccine: A Review of the Studies since the 1998 Wakefield Study | |
No. 2, March 2016 | Antidiabetic Treatments and Cardiovascular Implications | |
No. 1, February 2016 | 2015 in Review: Relevant Safety Updates and Ongoing Safety Concerns |
Volume 5 - 2015 |
||
Issue | Table of Contents | |
No. 8, December 2015 | Does Sacubitril/Valsartan Pose a Treatment Conundrum for Management of Heart Failure? | |
No. 7, November 2015 | Obesity and Related Sequelae: Are Medications the Answer? | |
No. 6, October 2015 | From Antidotes to Edoxaban: An Oral Anticoagulation Update | |
No. 5, August 2015 | Is Long-Term Proton Pump Inhibitor Treatment for GERD Worth the Risk? | |
No. 4, June 2015 | New Hypertension Guidelines: Do Blood Pressure Goals Need to Change with Age? | |
No. 3, May 2015 | Treating UTIs with the Tried and True | |
No. 2, March 2015 | Combating the Opioid Epidemic: Are Abuse-deterrent Formulations the Answer? | |
No. 1, February 2015 | Evaluation of High Dose SSRI Initiation in Pediatrics and Young Adults |
Volume 4 - 2014 |
||
Issue | Table of Contents | |
No. 8, November 2014 | Guidance Update for Prophylaxis of Respiratory Syncytial Virus | |
No. 7, October 2014 | What's New with Oral Anticoagulants? | |
No. 6, August 2014 | New Hepatitis C Antiviral Therapies: How should they be used in clinical practice? | |
No. 5, June 2014 | Update on New Therapies for Treating Major Depressive Disorder (MDD) | |
No. 4, May 2014 | New Cholesterol Guidelines: A Significant Shift in Cholesterol Management | |
No. 3, April 2014 | Second Generation Antipsychotics: Are these drugs effective in treating PTSD? | |
No. 2, March 2014 | Evidence Based Review of Fish Oil: Going Beyond the Headlines | |
No. 1, January 2014 | Strategies for Effective Monitoring and Management of Psychotropics in Children |
Volume 3 - 2013 |
||
Issue | Table of Contents | |
No. 5, November 2013 | Update on the New Oral Anticoagulants with a Focus on Apixaban | |
No. 4, October 2013 | Updates and Comparisons of Type 2 Diabetes Treatment Guidelines | |
No. 3, August 2013 |
Managing Metabolic Side Effects in Children Receiving Antipsychotics - Quick Reference Guides |
|
No. 2, July 2013 | Updates and Future Perspectives in the Management of Stable Chronic Obstructive Pulmonary Disease | |
No. 1, April 2013 | Management of Gout in the Presence of Chronic Kidney Disease |
Volume 2 - 2012 |
||
Issue | Table of Contents | |
No. 7, December 2012 | The Future of Newer Obesity Medications | |
No. 6, September 2012 | Do Spinosad or Ivermectin Have a Place in Head Lice Eradication? | |
No. 5, August 2012 | Triple Therapy with the New Hepatitis C Protease Inhibitors: Challenges and Strategies | |
No. 4, June 2012 | Can The Diabetic War Be Fought By Aggressive Blood Pressure Control? | |
No. 3, May 2012 | Is Prasugrel or Ticagrelor a Better Choice Than the New Generic Clopidogrel? | |
No. 2, March 2012 | Current Findings in the Off-Label Use of Atypical Antipsychotics | |
No. 1, January 2012 | RSV Prophylaxis: Updates and Recommendations |
Volume 1 - 2011 |
||
Issue | Table of Contents | |
No. 1, November 2011 | Atypical Antipsychotic Drug Class Review |
We hope the Oregon State Drug Review newsletter is useful, thought provoking and interesting to our readers. Questions, concerns, comments, or suggestions are always welcome and should be addressed to the managing editor:
Kathy Sentena
OSU College of Pharmacy - Drug Use Research & Management @
OHA Division of Medical Assistance Programs
500 Summer Street NE, E35
Salem, OR 97301-1079
Phone: (503) 947-5220
Fax: 503-947-2596
sentenak @ ohsu.edu